Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

[18f]fapi-74

Phase 3Radiopharmaceutical

NNational Heart, Lung, and Blood Institute (NHLBI)

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Allogeneic Stem Cell TransplantationNot yet recruiting

Allogeneic Stem Cell TransplantationPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q2 2033

Phase 3Not yet recruiting

Allogeneic Stem Cell Transplantation

NCT07613099

Clinical

Trials by Indication[1]

Allogeneic Stem Cell Transplantation1 trial

Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging)

Not yet recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT07613099·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [18f]fapi-74. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [18f]fapi-74. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Related News